Metabolomics for the masses: The future of metabolomics in a personalized world

New Horizons in Translational Medicine

Volumn 3, Issue 6, 2017, Pages 294-305

  Trivedi, Drupad K ^a   Hollywood, Katherine A ^a   Goodacre, Royston ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

DISEASE COURSE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HEALTH CARE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; METABOLOMICS; MULTICENTER STUDY (TOPIC); MYCOBACTERIUM TUBERCULOSIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 85025463270     PISSN: None     EISSN: 23075023     Source Type: Journal    
DOI: 10.1016/j.nhtm.2017.06.001     Document Type: Review

References (177)

1. Oliver, S.G., et al. Systematic functional analysis of the yeast genome. Trends Biotechnol. 16:9 (1998), 373–378.
2. Kell, D.B., Oliver, S.G., The metabolome 18 years on: a concept comes of age. Metabolomics, 12(9), 2016, 148.
3. Strimbu, K., Tavel, J.A., What are biomarkers?. Curr. Opin. HIV AIDS 5:6 (2010), 463–466.
4. Broadhurst, D.I., Kell, D.B., Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics 2:4 (2006), 171–196.
5. Poste, G., Bring on the biomarkers. Nature 469:7329 (2011), 156–157.
6. Nix, H., A National Geographic Information System - An Achievable Objective?, in: Keynote address, Aurisa, 1990.
7. Sansone, S., Goodacre, F.T., Griffin, R., Wardy, J.L., Kaddurah-Daouk, N.W., Kristal, R., London, B.S., Mendes, J., Morrison, P., Nikolau, N., Robertson, B., Sumner, D., Taylor, L.W., van der Werf, C., Ommen, M., Fiehn O, B.V., The metabolomics standards initiative. Nat. Biotechnol. 25:8 (2007), 846–848.
8. Statistics, Of.N., Registered deaths by age, sex, selected underlying causes of death, and the 10 leading causes of death for both males and females. Stat. Bull., 2015.
9. Commission, E., Causes of death - standardised death rate by residence. Eurostat, 2013.
10. O'Neill, J., Review on antimicrobial resistance. Antimicrob. Resist.: Tackling Crisis Health Wealth Nations, 2014.
11. Goodacre, R., Metabolomics of a superorganism. J. Nutr. 137:1 (2007), 259S–266S.
12. Potgieter, M., et al. The dormant blood microbiome in chronic, inflammatory diseases. FEMS Microbiol. Rev. 39:4 (2015), 567–591.
13. Kaufman, D.J., et al. A survey of US adults' opinions about conduct of a nationwide precision medicine Initiative® cohort study of genes and environment. PLoS One, 11(8), 2016, e0160461.
14. N.O.O. Communications, NIH funds biobank to support Precision Medicine Initiative Cohort Program, in: NIH News Releases, 2016. [online].
15. FDA, Precision Medicine. Science and Research Special Topics, 2016.
16. Beger, R.D., et al. Metabolomics enables precision medicine: “a white paper, community perspective”. Metabolomics, 12(9), 2016, 149.
17. Neavin, D., Kaddurah-Daouk, R., Weinshilboum, R., Pharmacometabolomics informs pharmacogenomics. Metabolomics, 12, 2016, 7.
18. Crockett, D., Crockett, D., (eds.) Going Beyond Genomics in Precision Medicine: What's Next, 2016, Healthcare Transformation and Precision Medicine https://www.healthcatalyst.com.
19. Clish, C.B., Metabolomics: an emerging but powerful tool for precision medicine. Mol. Case Stud., 1(1), 2015.
20. Monteiro, M.S., et al. Metabolomics analysis for biomarker discovery: advances and challenges. Curr. Med. Chem. 20:2 (2013), 257–271.
21. Armitage, E.G., Barbas, C., Metabolomics in cancer biomarker discovery: current trends and future perspectives. J. Pharm. Biomed. Anal. 87 (2014), 1–11.
22. Kell, D.B., Metabolomic biomarkers: search, discovery and validation. Expert Rev. Mol. Diagn. 7:4 (2007), 329–333.
23. Altadill, T., et al. Enabling metabolomics based biomarker discovery studies using molecular phenotyping of exosome-like vesicles. PLoS One, 11(3), 2016, e0151339.
24. Xia, J., et al. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics 9:2 (2013), 280–299.
25. Dhanasekaran, S.M., et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412:6849 (2001), 822–826.
26. Pashayan, N., Pharoah, P., Population-based screening in the era of genomics. Personal. Med. 9:4 (2012), 451–455.
27. Guo, L., et al. Plasma metabolomic profiles enhance precision medicine for volunteers of normal health. Proc. Natl. Acad. Sci. USA 112:35 (2015), E4901–E4910.
28. Vanmassenhove, J., et al. Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrol. Dial. Transplant. 28:2 (2013), 254–273.
29. Mathelin, C., et al. Serum biomarkers for detection of breast cancers: a prospective study. Breast Cancer Res. Treat. 96:1 (2006), 83–90.
30. Tessitore, A., et al. Serum biomarkers identification by mass spectrometry in high-mortality tumors. Int. J. Proteom., 2013, 2013, 15.
31. Chung, L., et al. Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer. Breast Cancer Res., 16(3), 2014, R63.
32. Shen, C., et al. Developing urinary metabolomic signatures as early bladder cancer diagnostic markers. Omics 19:1 (2015), 1–11.
33. Kim, K., et al. Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS: J. Integr. Biol. 15:5 (2011), 293–303.
34. Trivedi, D.K., Iles, R.K., Shotgun metabolomic profiles in maternal urine identify potential mass spectral markers of abnormal fetal biochemistry - dihydrouracil and progesterone in the metabolism of Down syndrome. Biomed. Chromatogr. 29:8 (2015), 1173–1183.
35. Laiakis, E.C., et al. Metabolomic analysis in severe childhood pneumonia in The Gambia, West Africa: findings from a pilot study. PLoS One, 5(9), 2010, e12655.
36. van de Kant, K.D.G., et al. Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review. Respir. Res., 13(1), 2012 (117-117).
37. R. Schnabel, et al., Analysis of volatile organic compounds in exhaled breath to diagnose ventilator-associated pneumonia. Scientific Reports. 5, 2015, p. 17179.
38. Sethi, S., Nanda, R., Chakraborty, T., Clinical application of volatile organic compound analysis for detecting infectious diseases. Clin. Microbiol. Rev. 26:3 (2013), 462–475.
39. Hollywood, K., Brison, D.R., Goodacre, R., Metabolomics: current technologies and future trends. Proteomics 6:17 (2006), 4716–4723.
40. Dunn, W.B., et al. Molecular phenotyping of a UK population: defining the human serum metabolome. Metabolomics 11 (2015), 9–26.
41. Ganna, A., et al. Large-scale metabolomic profiling identifies novel biomarkers for incident coronary heart disease. PLoS Genet., 10(12), 2014, e1004801.
42. Albright, J.C., et al. Large-scale metabolomics reveals a complex response of aspergillus nidulans to epigenetic perturbation. ACS Chem. Biol. 10:6 (2015), 1535–1541.
43. Harris, R., Overview of screening: where we are and where we may be headed. Epidemiol. Rev. 33:1 (2011), 1–6.
44. Khoury, M.J., McCabe, L.L., McCabe, E.R.B., Population screening in the age of genomic medicine. N. Engl. J. Med. 348:1 (2003), 50–58.
45. Munafò, M.R., et al. A manifesto for reproducible science. Nat. Hum. Behav., 1, 2017, 0021.
46. Dunn, W.B., et al. The importance of experimental design and QC samples in large-scale and MS-driven untargeted metabolomic studies of humans. Bioanalysis 4:18 (2012), 2249–2264.
47. Wen, H., et al. A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. J. Hepatol. 52:2 (2010), 228–233.
48. Costa e Silva, J.A., Personalized medicine in psychiatry: new technologies and approaches. Metabolism 62:Suppl. 1 (2013), S40–S44.
49. Harrer, S. Measuring Life: Sensors and Analytics for Precision Medicine, 2015.
50. Vaddiraju, S., et al. Technologies for Continuous Glucose Monitoring: current Problems and Future Promises. J. Diabetes Sci. Technol. 4:6 (2010), 1540–1562.
51. BinDhim, N.F., et al. Depression screening via a smartphone app: cross-country user characteristics and feasibility. J. Am. Med. Inform. Assoc. 22:1 (2015), 29–34.
52. Nam, H.S., et al. Development of smartphone application that aids stroke screening and identifying nearby acute stroke care hospitals. Yonsei Med. J. 55:1 (2014), 25–29.
53. C. Boletsis, S. McCallum, B.F. Landmark, The use of smartwatches for health monitoring in home-based dementia care, in: Human Aspects of IT for the Aged Population. Design for Everyday Life: First International Conference, ITAP 2015, Held as Part of HCI International 2015, Los Angeles, CA, USA, August 2–7, 2015. Proceedings, Part II, J. Zhou and G. Salvendy, Editors, Cham, Springer International Publishing, 2015, pp. 15–26.
54. Badugu, R., Lakowicz, J.R., Geddes, C.D., A glucose-sensing contact lens: from bench top to patient. Curr. Opin. Biotechnol. 16:1 (2005), 100–107.
55. Chu, M.X., et al. Soft contact lens biosensor for in situ monitoring of tear glucose as non-invasive blood sugar assessment. Talanta 83:3 (2011), 960–965.
56. Bodhani, A., The connected body. Eng. Technol. 10:4 (2015), 44–47.
57. Marschollek, M., et al. Wearable sensors in healthcare and sensor-enhanced health information systems: all our tomorrows?. Healthc. Inform. Res. 18:2 (2012), 97–104.
58. Sarkar, B.K., Big data for secure healthcare system: a conceptual design. Complex Intell. Syst., 2017, 1–19.
59. Park, S., Chung, K., Jayaraman, S., 1 - wearables: fundamentals, advancements, and a roadmap for the future A2 - Sazonov, Edward. Neuman, M.R., (eds.) Wearable Sensors, Chapter 1, 2014, Academic Press, Oxford, 1–23.
60. Bot, B.M., et al. The mPower study, Parkinson disease mobile data collected using Research Kit. Sci. Data, 3, 2016, 160011.
61. Reade, S., et al. Cloudy with a chance of pain: engagement and subsequent attrition of daily data entry in a smartphone pilot study tracking weather, disease severity, and physical activity in patients with rheumatoid arthritis. JMIR Mhealth Uhealth, 5(3), 2017, e37.
62. Long, E., et al. An artificial intelligence platform for the multihospital collaborative management of congenital cataracts. Nat. Biomed. Eng., 1, 2017, 0024.
63. Marr, B., First FDA approval for clinical cloud-based deep learning in healthcare. Forbes, 2017 (online).
64. Bonham, V.L., Callier, S.L., Royal, C.D., Will precision medicine move us beyond race?. N. Engl. J. Med. 374:21 (2016), 2003–2005.
65. Schmidt, M.A., Goodwin, T.J., Personalized medicine in human space flight: using Omics based analyses to develop individualized countermeasures that enhance astronaut safety and performance. Metabolomics 9:6 (2013), 1134–1156.
66. NASA, Metabolomic and Genomic Markers of Atherosclerosis as Related to Oxidative Stress, Inflammation, and Vascular Function in Twin Astronauts. ISS Science for Everyone, 2016.
67. NASA, Human Exploration Research Opportunities - Differential Effects on Homozygous Twin Astronauts Associated with Differences in Exposure to Spaceflight Factors ISS Science for Everyone, 2016.
68. Lindon, J.C., Nicholson, J.K., The emergent role of metabolic phenotyping in dynamic patient stratification. Expert Opin. Drug Metab. Toxicol. 10:7 (2014), 915–919.
69. Beger, R.D., et al. Metabolomics enables precision medicine: “a white paper, community perspective”. Metabolomics 12:10 (2016), 1–15.
70. Rattray, N.J.W., Daouk, R.K., PharmacometabOlomics and Precision Medicine Special Issue Editorial. Metabolomics, 13(5), 2017, 59.
71. Hippocrates, Aphorisms, in: The genuine works of Hippocrates: translated from the Greek with a preliminary discourse and annotations, London, Sydenham Society, 1849.
72. Kenny, L.C., et al. Novel biomarkers for pre-eclampsia detected using metabolomics and machine learning. Metabolomics, 1(3), 2005, 227.
73. Yang, J., et al. High performance liquid chromatography-mass spectrometry for metabonomics: potential biomarkers for acute deterioration of liver function in chronic hepatitis B. J. Proteome Res. 5:3 (2006), 554–561.
74. Holmes, E., et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med., 3(8), 2006, e327.
75. Yi, L.-Z., et al. Plasma fatty acid metabolic profiling and biomarkers of type 2 diabetes mellitus based on GC/MS and PLS-LDA. FEBS Lett. 580:30 (2006), 6837–6845.
76. Yin, P.Y., et al. Metabonomics study of intestinal fistulas based on ultraperformance liquid chromatography coupled with Q-TOF mass spectrometry (UPLC/Q-TOF MS). J. Proteome Res. 5:9 (2006), 2135–2143.
77. Kaddurah-Daouk, R., et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol. Psychiatry 12:10 (2007), 934–945.
78. Wikoff, W.R., et al. Metabolomics identifies perturbations in human disorders of propionate metabolism. Clin. Chem. 53:12 (2007), 2169–2176.
79. Bogdanov, M., et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131:2 (2008), 389–396.
80. Chen, J., et al. Practical approach for the identification and isomer elucidation of biomarkers detected in a metabonomic study for the discovery of individuals at risk for diabetes by integrating the chromatographic and mass spectrometric information. Anal. Chem. 80:4 (2008), 1280–1289.
81. Lawton, K.A., et al. Analysis of the adult human plasma metabolome. Pharmacogenomics 9:4 (2008), 383–397.
82. Yi, L.Z., et al. Plasma fatty acid metabolic profile coupled with uncorrelated linear discriminant analysis to diagnose and biomarker screening of type 2 diabetes and type 2 diabetic coronary heart diseases. Metabolomics 4:1 (2008), 30–38.
83. Erb, G., et al. Toward improved grading of malignancy in oligodendrogliomas using metabolomics. Magn. Reson. Med. 59:5 (2008), 959–965.
84. Yin, P., et al. Serum metabolic profiling of abnormal savda by liquid chromatography/mass spectrometry. J. Chromatogr. B 871:2 (2008), 322–327.
85. Seli, E., et al. Noninvasive metabolomic profiling of embryo culture media using proton nuclear magnetic resonance correlates with reproductive potential of embryos in women undergoing in vitro fertilization. Fertil. Steril. 90:6 (2008), 2183–2189.
86. Qiu, Y., et al. Multivariate classification analysis of metabolomic data for candidate biomarker discovery in type 2 diabetes mellitus. Metabolomics 4:4 (2008), 337–346.
87. Chan, E.C.Y., et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J. Proteome Res. 8:1 (2009), 352–361.
88. Zheng, X., et al. Plasma fatty acids metabolic profiling analysis of coronary heart disease based on GC–MS and pattern recognition. J. Pharm. Biomed. Anal. 49:2 (2009), 481–486.
89. Rudnick, D.A., et al. Serum α-NH(2)-butyric acid may predict spontaneous survival in pediatric acute liver failure. Pediatr. Transplant. 13:2 (2009), 223–230.
90. Vallejo, M., et al. Plasma fingerprinting with GC-MS in acute coronary syndrome. Anal. Bioanal. Chem. 394:6 (2009), 1517–1524.
91. Ahmed, S.S., et al. Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J. Biomed. Sci., 16(1), 2009, 63.
92. Wu, H., et al. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal. Chim. Acta 648:1 (2009), 98–104.
93. Zhang, J., et al. Metabonomics research of diabetic nephropathy and type 2 diabetes mellitus based on UPLC–oaTOF-MS system. Anal. Chim. Acta 650:1 (2009), 16–22.
94. Ritchie, S.A., et al. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med., 8(1), 2010, 13.
95. Sugimoto, M., et al. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics 6:1 (2010), 78–95.
96. Lokhov, P.G., et al. Metabolite profiling of blood plasma of patients with prostate cancer. Metabolomics 6:1 (2010), 156–163.
97. Kim, Y., et al. Multivariate classification of urine metabolome profiles for breast cancer diagnosis. BMC Bioinform., 11(2), 2010, S4.
98. Zhai, G., et al. Serum branched-chain amino acid to histidine ratio: a novel metabolomic biomarker of knee osteoarthritis. Ann. Rheum. Dis. 69:6 (2010), 1227–1231.
99. Li, N.-J., et al. Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry. Clin. Biochem. 43:12 (2010), 992–997.
100. 1H NMR metabonomic analysis in renal cell carcinoma: a possible diagnostic tool. J. Proteome Res. 9:8 (2010), 4038–4044.
101. Barnes, V.M., et al. Assessment of the effects of dentifrice on periodontal disease biomarkers in gingival crevicular fluid. J. Periodontol. 81:9 (2010), 1273–1279.
102. 1H NMR spectroscopy-based interventional metabolic phenotyping: a cohort study of rheumatoid arthritis patients. J. Proteome Res. 9:9 (2010), 4545–4553.
103. Chen, X., et al. Plasma metabolomics reveals biomarkers of the atherosclerosis. J. Sep. Sci. 33:17–18 (2010), 2776–2783.
104. Zhang, L., et al. Development and validation of a liquid chromatography–mass spectrometry metabonomic platform in human plasma of liver failure caused by hepatitis B virus. Acta Biochim. Biophys. Sin. 42:10 (2010), 688–698.
105. Denery, J.R., et al. Metabolomics-based discovery of diagnostic biomarkers for onchocerciasis. PLoS Negl. Trop. Dis., 4(10), 2010, e834.
106. Suhre, K., et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One, 5(11), 2010, e13953.
107. Romero, R., et al. Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery. J. Matern. Fetal Neonatal Med. 23:12 (2010), 1344–1359.
108. Dong, J., et al. Lysophosphatidylcholine profiling of plasma: discrimination of isomers and discovery of lung cancer biomarkers. Metabolomics 6:4 (2010), 478–488.
109. Madsen, R.K., et al. Diagnostic properties of metabolic perturbations in rheumatoid arthritis. Arthritis Res. Ther., 13(1), 2011, R19.
110. Saude, E.J., et al. Metabolomic profiling of asthma: diagnostic utility of urine nuclear magnetic resonance spectroscopy. J. Allergy Clin. Immunol. 127:3 (2011), 757–764 (e6).
111. Han, L.-D., et al. Plasma esterified and non-esterified fatty acids metabolic profiling using gas chromatography–mass spectrometry and its application in the study of diabetic mellitus and diabetic nephropathy. Anal. Chim. Acta 689:1 (2011), 85–91.
112. Chen, J., et al. Serum 27-nor-5β-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer. J. Proteome Res. 10:5 (2011), 2625–2632.
113. Lian, J.S., et al. A serum metabonomic study on the difference between alcohol- and HBV-induced liver cirrhosis by ultraperformance liquid chromatography coupled to mass spectrometry plus quadrupole time-of-flight mass spectrometry. Chin. Med. J. 124:9 (2011), 1367–1373.
114. Fong, M.Y., McDunn, J., Kakar, S.S., Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PLoS One, 6(5), 2011, e19963.
115. Tang, F., et al. Novel potential markers of nasopharyngeal carcinoma for diagnosis and therapy. Clin. Biochem. 44:8–9 (2011), 711–718.
116. Chen, T., et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol. Cell. Proteom., 10(7), 2011.
117. Kondo, Y., et al. Serum fatty acid profiling of colorectal cancer by gas chromatography/mass spectrometry. Biomark. Med. 5:4 (2011), 451–460.
118. Al-Mubarak, R., et al. Serum metabolomics reveals higher levels of polyunsaturated fatty acids in lepromatous leprosy: potential markers for susceptibility and pathogenesis. PLoS Negl. Trop. Dis., 5(9), 2011, e1303.
119. Munshi, S.U., et al. Metabonomic analysis of hepatitis E patients shows deregulated metabolic cycles and abnormalities in amino acid metabolism. J. Viral Hepat. 18:10 (2011), e591–e602.
120. Atzori, L., et al. Clinical metabolomics and urinary NGAL for the early prediction of chronic kidney disease in healthy adults born ELBW. J. Matern. Fetal Neonatal. Med. 24:sup. 2 (2011), 40–43.
121. Chen, F., et al. Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method. Anal. Bioanal. Chem., 401(6), 2011, 1899.
122. Hori, S., et al. A metabolomic approach to lung cancer. Lung Cancer 74:2 (2011), 284–292.
123. Duan, H., et al. Identification of biomarkers for melamine-induced nephrolithiasis in young children based on ultra high performance liquid chromatography coupled to time-of-flight mass spectrometry (U-HPLC–Q-TOF/MS). J. Chromatogr. B 879:30 (2011), 3544–3550.
124. Arlt, W., et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J. Clin. Endocrinol. Metab. 96:12 (2011), 3775–3784.
125. Putluri, N., et al. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res. 71:24 (2011), 7376–7386.
126. Shah, S.H., et al. Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. Am. Heart J., 163(5), 2012 (844-+).
127. Sato, Y., et al. Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. J. Lipid Res. 53:3 (2012), 567–576.
128. van der Kloet, F.M., et al. Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study). Metabolomics 8:1 (2012), 109–119.
129. Ikeda, A., et al. Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed. Chromatogr. 26:5 (2012), 548–558.
130. Schmerler, D., et al. Targeted metabolomics for discrimination of systemic inflammatory disorders in critically ill patients. J. Lipid Res. 53:7 (2012), 1369–1375.
131. Zhang, T., et al. Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry. Clin. Chim. Acta 413:9–10 (2012), 861–868.
132. Sun, J.C., et al. Serum metabolomic profiles from patients with acute kidney injury: a pilot study. J. Chromatogr. B-Anal. Technol. Biomed. Life Sci. 893 (2012), 107–113.
133. Vouk, K., et al. Discovery of phosphatidylcholines and sphingomyelins as biomarkers for ovarian endometriosis. Hum. Reprod. 27:10 (2012), 2955–2965.
134. Lv, W.W., Yang, T.S., Identification of possible biomarkers for breast cancer from free fatty acid profiles determined by GC-MS and multivariate statistical analysis. Clin. Biochem. 45:1–2 (2012), 127–133.
135. Xu, H.B., et al. Potential clinical utility of plasma amino acid profiling in the detection of major depressive disorder. Psychiatry Res. 200:2–3 (2012), 1054–1057.
136. Menni, C., et al. Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes 62:12 (2013), 4270–4276.
137. Yang, J., et al. Potential metabolite markers of schizophrenia. Mol. Psychiatry 18:1 (2013), 67–78.
138. McDunn, J.E., et al. Metabolomic signatures of aggressive prostate cancer. Prostate 73:14 (2013), 1547–1560.
139. Jung, J., et al. Serum metabolomics reveals pathways and biomarkers associated with asthma pathogenesis. Clin. Exp. Allergy 43:4 (2013), 425–433.
140. Zhang, A.H., et al. Urinary metabolic biomarker and pathway study of hepatitis B virus infected patients based on UPLC-MS system. PLoS One, 8(5), 2013.
141. Wang, L., et al. H-1-NMR based metabonomic profiling of human esophageal cancer tissue. Mol. Cancer, 2013, 12.
142. Wang, H.J., et al. H-1 NMR-based metabolic profiling of human rectal cancer tissue. Mol. Cancer, 2013, 12.
143. Wang, J., et al. Metabolomic identification of diagnostic plasma biomarkers in humans with chronic heart failure. Mol. Biosyst. 9:11 (2013), 2618–2626.
144. Liu, R., et al. Identification of plasma metabolomic profiling for diagnosis of esophageal squamous-cell carcinoma using an UPLC/TOF/MS platform. Int. J. Mol. Sci. 14:5 (2013), 8899–8911.
145. Rizza, S., et al. Metabolomics signature improves the prediction of cardiovascular events in elderly subjects. Atherosclerosis 232:2 (2014), 260–264.
146. Jin, X., et al. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. Oncotarget 5:6 (2014), 1635–1645.
147. Dawiskiba, T., et al. Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases. World J. Gastroenterol. 20:1 (2014), 163–174.
148. Wang, G., et al. Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment. J. Proteome Res. 13:5 (2014), 2649–2658.
149. Mathe, E.A., et al. Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. Cancer Res. 74:12 (2014), 3259–3270.
150. Reinke, S.N., et al. Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis. Mult. Scler. 20:10 (2014), 1396–1400.
151. Graham, S.F., Holscher, C., Green, B.D., Metabolic signatures of human Alzheimer's disease (AD): H-1 NMR analysis of the polar metabolome of post-mortem brain tissue. Metabolomics 10:4 (2014), 744–753.
152. Wang, Q., et al. Measurement of salivary metabolite biomarkers for early monitoring of oral cancer with ultra performance liquid chromatography-mass spectrometry. Talanta 119 (2014), 299–305.
153. Liu, X., et al. Discovery and validation of plasma biomarkers for major depressive disorder classification based on liquid chromatography-mass spectrometry. J. Proteome Res. 14:5 (2015), 2322–2330.
154. Drogan, D., et al. Untargeted metabolic profiling identifies altered serum metabolites of type 2 diabetes mellitus in a prospective, nested case control study. Clin. Chem. 61:3 (2015), 487–497.
155. Calderon-Santiago, M., et al. Human sweat metabolomics for lung cancer screening. Anal. Bioanal. Chem. 407:18 (2015), 5381–5392.
156. Pieragostino, D., et al. An integrated metabolomics approach for the research of new cerebrospinal fluid biomarkers of multiple sclerosis. Mol. Biosyst. 11:6 (2015), 1563–1572.
157. Miyamoto, S., et al. Systemic metabolomic changes in blood samples of lung cancer patients identified by gas chromatography time-of-flight mass spectrometry. Metabolites 5:2 (2015), 192–210.
158. Luan, H., et al. LC-MS-based urinary metabolite signatures in idiopathic Parkinson's disease. J. Proteome Res. 14:1 (2015), 467–478.
159. Trivedi, D.K., Iles, R.K., Shotgun metabolomic profiles in maternal urine identify potential mass spectral markers of abnormal fetal biochemistry – dihydrouracil and progesterone in the metabolism of Down syndrome. Biomed. Chromatogr. 29:8 (2015), 1173–1183.
160. Livshits, G., et al. An omics investigation into chronic widespread musculoskeletal pain reveals epiandrosterone sulfate as a potential biomarker. Pain 156:10 (2015), 1845–1851.
161. Dieme, B., et al. Metabolomics study of urine in autism spectrum disorders using a multiplatform analytical methodology. J. Proteome Res. 14:12 (2015), 5273–5282.
162. Guo, L., et al. Three plasma metabolite signatures for diagnosing high altitude pulmonary edema. Sci. Rep., 5, 2015.
163. Venter, L., et al. Untargeted urine metabolomics reveals a biosignature for muscle respiratory chain deficiencies. Metabolomics 11:1 (2015), 111–121.
164. Liang, Q., et al. Metabolomics-based screening of salivary biomarkers for early diagnosis of Alzheimer's disease. RSC Adv. 5:116 (2015), 96074–96079.
165. Embade, N., et al. Metabolic characterization of advanced liver fibrosis in HCV patients as studied by serum H-1-NMR spectroscopy. PLoS One, 11(5), 2016.
166. Chan, A.W., et al. H-1-NMR urinary metabolomic profiling for diagnosis of gastric cancer. Br. J. Cancer 114:1 (2016), 59–62.
167. Cameron, S.J.S., et al. The metabolomic detection of lung cancer biomarkers in sputum. Lung Cancer 94 (2016), 88–95.
168. Di Gangi, I.M., et al. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites. Oncotarget 7:5 (2016), 5815–5829.
169. Wang, H., et al. Potential serum biomarkers from a metabolomics study of autism. J. Psychiatry Neurosci. 41:1 (2016), 27–37.
170. Farshidfar, F., et al. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics. Br. J. Cancer 115:7 (2016), 848–857.
171. Smolenska, Z., Smolenski, R.T., Zdrojewski, Z., Plasma concentrations of amino acid and nicotinamide metabolites in rheumatoid arthritis–potential biomarkers of disease activity and drug treatment. Biomarkers 21:3 (2016), 218–224.
172. Kind, T., et al. Interstitial cystitis-associated urinary metabolites identified by mass-spectrometry based metabolomics analysis. Sci. Rep., 6, 2016, 39227.
173. Shao, X., et al. Screening and verifying endometrial carcinoma diagnostic biomarkers based on a urine metabolomic profiling study using UPLC-Q-TOF/MS. Clin. Chim. Acta 463 (2016), 200–206.
174. Chen, T., et al. Biomarker identification and pathway analysis of preeclampsia based on serum metabolomics. Biochem. Biophys. Res. Commun. 485:1 (2017), 119–125.
175. Kang, H., et al. Exploration of candidate biomarkers for human psoriasis based on gas chromatography-mass spectrometry serum metabolomics. Br. J. Dermatol. 176:3 (2017), 713–722.
176. Ellis, D.I., Dunn, W.B., Griffin, J.L., Allwood, J.W. and Goodacre, R. Metabolic fingerprinting as a diagnostic tool. Pharmacogenomics 8 (2007), 1243-1266.
177. Van der Greef, J., Stroobant, P. and van der Heijden, R. The role of analytical sciences in medical systems biology. Curr. Opin. Chem. Biol. 8 (2004), 559-565.